Long-term insulin independence and improvement in insulin secretion after supplemental islet infusion under exenatide and etanercept

Transplantation

Volumn 86, Issue 12, 2008, Pages 1658-1665

  Faradji, Raquel N ^a,e   Tharavanij, Thipaporn ^a,b,e   Messinger, Shari ^a,e   Froud, Tatiana ^a,e   Pileggi, Antonello ^a,e   Monroy, Kathy ^a,e   Mineo, Davide ^a,c,e   Baidal, David A ^a,e   Cure, Pablo ^a,e   Ponte, Gaston ^a,e   Mendez, Armando J ^a,e   Selvaggi, Gennaro ^a,e   Ricordi, Camillo ^a,e   Alejandro, Rodolfo ^a,d,e  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b THAMMASAT UNIVERSITY   (Thailand)

^c UNIVERSITY OF ROME TOR VERGATA   (Italy)

^d DIABETES RESEARCH INSTITUTE   (United States)

^e NONE   (Mexico)

Author keywords

Diabetes; Etanercept; Exenatide; Glucagon; Graft dysfunction; Insulin; Insulin independence; Islet; Islet transplantation; Metabolism

Indexed keywords

DACLIZUMAB; ETANERCEPT; EXENDIN 4; INSULIN; RAPAMYCIN; TACROLIMUS; ANTIDIABETIC AGENT; C PEPTIDE; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; PEPTIDE; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR; UNCLASSIFIED DRUG; VENOM;

ADULT; ALLOTRANSPLANTATION; ARTICLE; CLINICAL STUDY; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; DRUG EFFECT; ENGRAFTMENT; FOLLOW UP; GRAFT DYSFUNCTION; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; HYPERGLUCAGONEMIA; IMMUNOSUPPRESSIVE TREATMENT; INSULIN RELEASE; INTRAVENOUS GLUCOSE TOLERANCE TEST; METABOLISM; NAUSEA; PANCREAS ISLET TRANSPLANTATION; PILOT STUDY; PRIORITY JOURNAL; RANDOMIZATION; SAMPLE SIZE; TEST MEAL; BLOOD; BODY WEIGHT; GLUCOSE BLOOD LEVEL; IMMUNOLOGY; METHODOLOGY; MIDDLE AGED; SECRETION; TREATMENT FAILURE;

ADULT; BLOOD GLUCOSE; BODY WEIGHT; C-PEPTIDE; FOLLOW-UP STUDIES; GRAFT SURVIVAL; HUMANS; HYPOGLYCEMIC AGENTS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; INSULIN; ISLETS OF LANGERHANS TRANSPLANTATION; MIDDLE AGED; PEPTIDES; RECEPTORS, TUMOR NECROSIS FACTOR; TREATMENT FAILURE; VENOMS;

EID: 58849144338     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31818fe448     Document Type: Article

References (32)

1. Ryan EA, Paty BW, Senior PA, et al. Five-year follow-up after clinical islet transplantation. Diabetes 2005; 54: 2060.
2. Shapiro AM, Ricordi C, Hering BJ, et al. International trial of the Edmonton protocol for islet transplantation. N Engl J Med 2006; 355: 1318.
3. Close N, Alejandro R, Hering B, et al. Second annual analysis of the collaborative islet transplant registry. Transplant Proc 2007; 39: 179.
4. Froud T, Ricordi C, Baidal DA, et al. Islet transplantation in type 1 diabetes mellitus using cultured islets and steroid-free immunosup-pression: Miami experience. Am J Transplant 2005; 5: 2037.
5. Poggioli R, Faradji RN, Ponte G, et al. Quality of life after islet transplantation. Am J Transplant 2006; 6: 371.
6. Drucker D. Glucagon-like peptides: Regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol 2003; 17: 161.
7. Nauck MA, Meier JJ. Glucagon-like peptide 1 and its derivatives in the treatment of diabetes. Regul Pept 2005; 128:135.
8. D'Amico E, Hui H, Khoury N, et al. Pancreatic beta-cells expressing GLP-1 are resistant to the toxic effects of immunosuppressive drugs. J Mol Endocrinol 2005; 34: 377.
9. Toyoda K, Okitsu T, Yamane S, et al. GLP-1 receptor signaling protects pancreatic beta cells in intraportal islet transplant by inhibiting apoptosis. Biochem Biophys Res Commun 2008; 367: 793.
10. Xu G, Stoffers DA, Habener JF, et al. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999; 48: 2270.
11. Stoffers DA, Kieffer TJ, Hussain MA,etal. Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas. Diabetes 2000; 49: 741.
12. Farilla L, Hui H, Bertolotto C, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002; 143: 4397.
13. Fung M, Thompson D, Shapiro RJ, et al. Effect of glucagon-like peptide-1 (7-37) on beta-cell function after islet transplantation in type 1 diabetes. Diabetes Res Clin Pract 2006; 74: 189.
14. Ghofaili KA, Fung M, Ao Z, et al. Effect of exenatide on beta cell function after islet transplantation in type 1 diabetes. Transplantation 2007; 83: 24.
15. Froud T, Faradji RN, Pileggi A, et al. The use of exenatide in islet transplant recipients with chronic allograft dysfunction: Safety, efficacy, and metabolic effects. Transplantation 2008; 86: 36.
16. Rabinovitch A, Sumoski W, Rajotte RV, et al. Cytotoxic effects of cytokines on human pancreatic islet cells in monolayer culture. J Clin Endocrinol Metab 1990; 71: 152.
17. Farney AC, Xenos E, Sutherland DE, et al. Inhibition of pancreatic islet beta cell function by tumor necrosis factor is blocked by a soluble tumor necrosis factor receptor. Transplant Proc 1993; 25: 865.
18. Hering B, Kandaswamy R, Ansite J, et al. Single-donor, marginal-dose islet transplantation in patients with type 1 diabetes. JAMA 2005; 293: 830.
19. Gangemi A, Salehi P, Hatipoglu B, et al. Islet transplantation for brittle type 1 diabetes: The UIC protocol. Am J Transplant 2008; 8: 1250.
20. Baidal D, Froud T, Hafiz M, et al. Acute insulin release to intravenous glucose is the best indicator of islet allograft dysfunction. Transplantation 2004; 78(suppl 1): 177.
21. Faradji RN, Monroy K, Messinger S, et al. Simple measures to monitor beta-cell mass and assess islet graft dysfunction. Am J Transplant 2007; 7: 303.
22. Ricordi C, Lacy PE, Finke EH, et al. Automated method for isolation of human pancreatic islets. Diabetes 1988; 37: 413.
23. Ichii H, Pileggi A, Molano RD, et al. Rescue purification maximizes the use of human islet preparations for transplantation. Am J Transplant 2005; 5: 21.
24. Hafiz MM, Faradji RN, Froud T, et al. Immunosuppression and procedure-related complications in 26 patients with type 1 diabetes mellitus receiving allogeneic islet cell transplantation. Transplantation 2005; 80: 1718.
25. Scharp DW, Lacy PE, Weide LG, et al. Intraportal islet allografts: The use of a stimulation index to represent functional results. Transplant Proc 1991; 23(1 Pt 1): 796.
26. Exenatide: AC 2993, AC002993, AC2993A, Exendin 4, LY2148568. Drugs R D 2004; 5: 35.
27. Fehse F, Trautmann M, Holst JJ, et al. Exenatide augments first-and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2005; 90: 5991.
28. Yusta B, Baggio LL, Estall JL, et al. GLP-1 receptor activation improves beta cell function and survival following induction of endoplasmic reticulum stress. Cell Metab 2006; 4: 391.
29. Greenbaum CJ, Prigeon RL, D'Alessio DA. Impaired beta-cell function, incretin effect, and glucagon suppression in patients with type 1 diabetes who have normal fasting glucose. Diabetes 2002; 51: 951.
30. Muller WA, Faloona GR, Aguilar-Parada E, et al. Abnormal alpha-cell function in diabetes. Response to carbohydrate and protein ingestion. N Engl J Med 1970; 283: 109.
31. Vilsboll T, Krarup T, Sonne J, et al. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab 2003; 88: 2706.
32. Froud T, Faradji RN, Tharavanij T, et al. Use of acetaminophen during mixed meal testing to assess the effect of exenatide on gastric emptying in islet transplant recipients. Am J Transplant 2008; 8(suppl 2): 434.